Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1647
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18584551 | ANTI-ACVR1 ANTIBODIES AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17640293 | THERAPEUTIC FUSION PROTEINS | Final Rejection | NOVARTIS AG |
| 16761513 | METHOD OF TREATING HIDRADENTITIS SUPPURATIVA WITH IL-17 ANTAGONISTS | Final Rejection | NOVARTIS AG |
| 17773886 | HIGH SALT LOAD CONDITIONING DURING CATION EXCHANGE CHROMATOGRAPHY TO REMOVE PRODUCT-RELATED IMPURITIES | Non-Final OA | AMGEN INC. |
| 18032080 | FORMULATION FOR WOUND HEALING | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 17760984 | CAMPHORSULFONIC ACID AND COMBINATIONS THEREOF WITH CATIONIC EXCIPIENTS AS VISCOSITY REDUCING AGENTS IN HIGH CONCENTRATED PROTEIN FORMULATIONS | Non-Final OA | MERCK PATENT GMBH |
| 17635560 | IMMUNE CELLS FOR ADOPTIVE CELL THERAPIES | Final Rejection | Board of Regents, The University of Texas System |
| 18232648 | COMPOSITIONS AND METHODS FOR TREATING BREAST CANCER | Non-Final OA | Arizona Board of Regents on Behalf of The University of Arizona |
| 17289420 | TREATMENT OF ANEMIA DUE TO VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS USING ACTIVIN-ACTRll LIGAND TRAPS | Final Rejection | Acceleron Pharma Inc. |
| 18637050 | ANTIBODY-DRUG CONJUGATE | Non-Final OA | GENAHEAD BIO, INC. |
| 17476803 | INHIBIN AS TARGETABLE REGULATORS OF ANGIOGENESIS | Final Rejection | UNIVERSITY OF SOUTH CAROLINA |
| 17327504 | METHODS FOR TREATING EOSINOPHILIC ESOPHAGITIS BY ADMINISTERING AN IL-4R INHIBITOR | Non-Final OA | SANOFI BIOTECHNOLOGY |
| 18031345 | THERAPEUTIC MODULATION OF ALCAM/CD166 | Non-Final OA | I2DX, INC. |
| 17906730 | VEGF DIMER MOLECULES AND COLUMNS COMPRISING A VEGF DIMER MOLECULE AS WELL AS USES, PRODUCTION METHODS AND METHODS INVOLVING THE SAME | Non-Final OA | Universität Zu Köln |
| 17242954 | IgA mediated killing of aberrant cells by CD47- SIRPalpha checkpoint inhibition of neutrophils | Non-Final OA | UMC Utrecht Holding B.V. |
| 18022358 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | Non-Final OA | Trames Bio, Inc. |
| 18019160 | COMPOSITION AND METHOD FOR TREATING NEUROPATHY | Final Rejection | The Steadman Clinic & Steadman Philippon Research Institute |
| 18069585 | RECOMBINANT MODIFIED FIBROBLAST GROWTH FACTORS AND THERAPEUTIC USES THEREOF | Final Rejection | Trefoil Therapeutics, Inc. |
| 17651064 | PIF BINDING AS A MARKER FOR IMMUNE DYSREGULATION | Final Rejection | Prince Biotech, LLC |
| 17367666 | USE OF NEGATIVE FUNCTIONAL MODULATORS OF ERYTHROPOIETIN FOR THERAPY | Final Rejection | ANDREMACON S.R.L. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy